Regulation of T cell receptor complex-mediated signaling by ubiquitin and ubiquitin-like modifications

American Journal of Clinical and Experimental Immunology

Volumn 3, Issue 3, 2014, Pages 107-123

  Friend, Samantha F ^a,b   Deason Towne, Francina ^a,c   Peterson, Lisa K ^a,b   Berger, Allison J ^d   Dragone, Leonard L ^a,b,e,f  

^a Children's Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c REGIS UNIVERSITY   (United States)

^d TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^e CHILDREN S HOSPITAL COLORADO   (United States)

^f NONE   (United States)

Author keywords

c Cbl; MLN4924; NEDD8; SLAP; SUMO; T cell; Ubiquitin

Indexed keywords

BORTEZOMIB; C IAP1 PROTEIN; C IAP2 PROTEIN; CARFILZOMIB; CBL PROTEIN; CUL1 PROTEIN; CUL2 PROTEIN; CUL3 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GRAIL PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ITCH PROTEIN; NEDD8 PROTEIN; PELLINO 1 PROTEIN; PEPTIDES AND PROTEINS; PEVONEDISTAT; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE ZAP 70; SRC LIKE ADAPTOR PROTEIN; STUB1 PROTEIN; SUMO PROTEIN; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ZETA; TRIM21 PROTEIN; TRIM27 PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE NEDD4; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; CD4 T LYMPHOCYTE; CELL PROLIFERATION; CYTOKINE PRODUCTION; DOWN REGULATION; HUMAN; INFLAMMATION; NEDDYLATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SUMOYLATION; T LYMPHOCYTE ACTIVATION; UBIQUITINATION; UPREGULATION;

EID: 84969323239     PISSN: None     EISSN: 21647712     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Krishna RG and Wold F. Post-translational modification of proteins. Adv Enzymol Relat Areas Mol Biol 1993; 67: 265-298.
2. Doyle HA and Mamula MJ. Post-translational protein modifications in antigen recognition and autoimmunity. Trends Immunol 2001; 22: 443-449.
3. Komander D and Rape M. The ubiquitin code. Annu Rev Biochem 2012; 81: 203-229.
4. Hershko A. Ubiquitin-mediated protein degradation. J Biol Chem 1988; 263: 15237-15240.
5. Hershko A and Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425-479.
6. Lorenz S, Cantor AJ, Rape M and Kuriyan J. Macromolecular juggling by ubiquitylation enzymes. BMC Biol 2013; 11: 65.
7. Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem 2001; 70: 503-533.
8. D'Andrea A and Pellman D. Deubiquitinating enzymes: a new class of biological regulators. Crit Rev Biochem Mol Biol 1998; 33: 337-352.
9. Fraile JM, Quesada V, Rodriguez D, Freije JM and Lopez-Otin C. Deubiquitinases in cancer: new functions and therapeutic options. Oncogene 2012; 31: 2373-2388.
10. Liu YC and Gu H. Cbl and Cbl-b in T-cell regulation. Trends Immunol 2002; 23: 140-143.
11. Naramura M, Jang IK, Kole H, Huang F, Haines D and Gu H. c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation. Nat Immunol 2002; 3: 1192-1199.
12. Miyake S, Lupher ML Jr, Druker B and Band H. The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor alpha. Proc Natl Acad Sci U S A 1998; 95: 7927-7932.
13. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S and Yarden Y. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 1999; 4: 1029-1040.
14. Naramura M, Kole HK, Hu RJ and Gu H. Altered thymic positive selection and intracellular signals in Cbl-deficient mice. Proc Natl Acad Sci U S A 1998; 95: 15547-15552.
15. Thien CB, Bowtell DD and Langdon WY. Perturbed regulation of ZAP-70 and sustained tyrosine phosphorylation of LAT and SLP-76 in c-Cbl-deficient thymocytes. J Immunol 1999; 162: 7133-7139.
16. Wang HY, Altman Y, Fang D, Elly C, Dai Y, Shao Y and Liu YC. Cbl promotes ubiquitination of the T cell receptor zeta through an adaptor function of Zap-70. J Biol Chem 2001; 276: 26004-26011.
17. Magnan A, Di Bartolo V, Mura AM, Boyer C, Richelme M, Lin YL, Roure A, Gillet A, Arrieumerlou C, Acuto O, Malissen B and Malissen M. T cell development and T cell responses in mice with mutations affecting tyrosines 292 or 315 of the ZAP-70 protein tyrosine kinase. J Exp Med 2001; 194: 491-505.
18. Kadlecek TA, van Oers NS, Lefrancois L, Olson S, Finlay D, Chu DH, Connolly K, Killeen N and Weiss A. Differential requirements for ZAP-70 in TCR signaling and T cell development. J Immunol 1998; 161: 4688-4694.
19. Myers MD, Sosinowski T, Dragone LL, White C, Band H, Gu H and Weiss A. Src-like adaptor protein regulates TCR expression on thymocytes by linking the ubiquitin ligase c-Cbl to the TCR complex. Nat Immunol 2006; 7: 57-66.
20. Tang J, Sawasdikosol S, Chang JH and Burakoff SJ. SLAP, a dimeric adapter protein, plays a functional role in T cell receptor signaling. Proc Natl Acad Sci U S A 1999; 96: 9775-9780.
21. Sosinowski T, Pandey A, Dixit VM and Weiss A. Src-like adaptor protein (SLAP) is a negative regulator of T cell receptor signaling. J Exp Med 2000; 191: 463-474.
22. Sosinowski T, Killeen N and Weiss A. The Src-like adaptor protein downregulates the T cell receptor on CD4+CD8+ thymocytes and regulates positive selection. Immunity 2001; 15: 457-466.
23. Myers MD, Dragone LL and Weiss A. Src-like adaptor protein down-regulates T cell receptor (TCR)-CD3 expression by targeting TCRzeta for degradation. J Cell Biol 2005; 170: 285-294.
24. Dragone LL, Shaw LA, Myers MD and Weiss A. SLAP, a regulator of immunoreceptor ubiquitination, signaling, and trafficking. Immunol Rev 2009; 232: 218-228.
25. Peterson LK, Shaw LA, Joetham A, Sakaguchi S, Gelfand EW and Dragone LL. SLAP deficiency enhances number and function of regulatory T cells preventing chronic autoimmune arthritis in SKG mice. J Immunol 2011; 186: 2273-2281.
26. Ouchida R, Yamasaki S, Hikida M, Masuda K, Kawamura K, Wada A, Mochizuki S, Tagawa M, Sakamoto A, Hatano M, Tokuhisa T, Koseki H, Saito T, Kurosaki T and Wang JY. A lysosomal protein negatively regulates surface T cell antigen receptor expression by promoting CD3zeta-chain degradation. Immunity 2008; 29: 33-43.
27. Kawai Y, Ouchida R, Yamasaki S, Dragone L, Tsubata T and Wang JY. LAPTM5 promotes lysosomal degradation of intracellular CD3zeta but not of cell surface CD3zeta. Immunol Cell Biol 2014; 92: 527-34.
28. Friend SF, Peterson LK, Kedl RM and Dragone LL. SLAP deficiency increases TCR avidity leading to altered repertoire and negative selection of cognate antigen-specific CD8(+) T cells. Immunol Res 2013; 55: 116-124.
29. Langdon WY, Hyland CD, Grumont RJ and Morse HC 3rd. The c-cbl proto-oncogene is preferentially expressed in thymus and testis tissue and encodes a nuclear protein. J Virol 1989; 63: 5420-5424.
30. Bachmaier K, Krawczyk C, Kozieradzki I, Kong YY, Sasaki T, Oliveira-dos-Santos A, Mariathasan S, Bouchard D, Wakeham A, Itie A, Le J, Ohashi PS, Sarosi I, Nishina H, Lipkowitz S and Penninger JM. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 2000; 403: 211-216.
31. Chiang YJ, Kole HK, Brown K, Naramura M, Fukuhara S, Hu RJ, Jang IK, Gutkind JS, Shevach E and Gu H. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 2000; 403: 216-220.
32. Fang D and Liu YC. Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells. Nat Immunol 2001; 2: 870-875.
33. Kipreos ET, Lander LE, Wing JP, He WW and Hedgecock EM. cul-1 is required for cell cycle exit in C. elegans and identifies a novel gene family. Cell 1996; 85: 829-839.
34. Duda DM, Borg LA, Scott DC, Hunt HW, Hammel M and Schulman BA. Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of conjugation. Cell 2008; 134: 995-1006.
35. Hori T, Osaka F, Chiba T, Miyamoto C, Okabayashi K, Shimbara N, Kato S and Tanaka K. Covalent modification of all members of human cullin family proteins by NEDD8. Oncogene 1999; 18: 6829-6834.
36. Dias DC, Dolios G, Wang R and Pan ZQ. CUL7: A DOC domain-containing cullin selectively binds Skp1.Fbx29 to form an SCF-like complex. Proc Natl Acad Sci U S A 2002; 99: 16601-16606.
37. Lyapina S, Cope G, Shevchenko A, Serino G, Tsuge T, Zhou C, Wolf DA, Wei N, Shevchenko A and Deshaies RJ. Promotion of NEDD-CUL1 conjugate cleavage by COP9 signalosome. Science 2001; 292: 1382-1385.
38. Zheng J, Yang X, Harrell JM, Ryzhikov S, Shim EH, Lykke-Andersen K, Wei N, Sun H, Kobayashi R and Zhang H. CAND1 binds to unneddylated CUL1 and regulates the formation of SCF ubiquitin E3 ligase complex. Mol Cell 2002; 10: 1519-1526.
39. Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, Manning AM, Andersen JS, Mann M, Mercurio F and Ben-Neriah Y. Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature 1998; 396: 590-594.
40. Feldman RM, Correll CC, Kaplan KB and Deshaies RJ. A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p. Cell 1997; 91: 221-230.
41. Sidow A, Bulotsky MS, Kerrebrock AW, Birren BW, Altshuler D, Jaenisch R, Johnson KR and Lander ES. A novel member of the F-box/WD40 gene family, encoding dactylin, is disrupted in the mouse dactylaplasia mutant. Nat Genet 1999; 23: 104-107.
42. Cardozo T and Pagano M. The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol 2004; 5: 739-751.
43. Sun Y and Li H. Functional characterization of SAG/RBX2/ROC2/RNF7, an antioxidant protein and an E3 ubiquitin ligase. Protein Cell 2013; 4: 103-116.
44. Bennett EJ, Rush J, Gygi SP and Harper JW. Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics. Cell 2010; 143: 951-965.
45. Liu B, Zheng Y, Wang TD, Xu HZ, Xia L, Zhang J, Wu YL, Chen GQ and Wang LS. Proteomic identification of common SCF ubiquitin ligase FBXO6-interacting glycoproteins in three kinds of cells. J Proteome Res 2012; 11: 1773-1781.
46. Petroski MD and Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 2005; 6: 9-20.
47. Hua Z and Vierstra RD. The cullin-RING ubiquitin-protein ligases. Annu Rev Plant Biol 2011; 62: 299-334.
48. Russell RC, Sufan RI, Zhou B, Heir P, Bunda S, Sybingco SS, Greer SN, Roche O, Heathcote SA, Chow VW, Boba LM, Richmond TD, Hickey MM, Barber DL, Cheresh DA, Simon MC, Irwin MS, Kim WY and Ohh M. Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. Nat Med 2011; 17: 845-853.
49. Mathew R, Seiler MP, Scanlon ST, Mao AP, Constantinides MG, Bertozzi-Villa C, Singer JD and Bendelac A. BTB-ZF factors recruit the E3 ligase cullin 3 to regulate lymphoid effector programs. Nature 2012; 491: 618-621.
50. Kawaida R, Yamada R, Kobayashi K, Tokuhiro S, Suzuki A, Kochi Y, Chang X, Sekine A, Tsunoda T, Sawada T, Furukawa H, Nakamura Y and Yamamoto K. CUL1, a component of E3 ubiquitin ligase, alters lymphocyte signal transduction with possible effect on rheumatoid arthritis. Genes Immun 2005; 6: 194-202.
51. An P, Duggal P, Wang LH, O'Brien SJ, Donfield S, Goedert JJ, Phair J, Buchbinder S, Kirk GD and Winkler CA. Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals. PLoS Genet 2007; 3: e19.
52. Whiting CC, Su LL, Lin JT and Fathman CG. GRAIL: a unique mediator of CD4 T-lymphocyte unresponsiveness. FEBS J 2011; 278: 47-58.
53. Lin JT, Lineberry NB, Kattah MG, Su LL, Utz PJ, Fathman CG and Wu L. Naive CD4 t cell proliferation is controlled by mammalian target of rapamycin regulation of GRAIL expression. J Immunol 2009; 182: 5919-5928.
54. Kriegel MA, Rathinam C and Flavell RA. E3 ubiquitin ligase GRAIL controls primary T cell activation and oral tolerance. Proc Natl Acad Sci U S A 2009; 106: 16770-16775.
55. Nurieva RI, Zheng S, Jin W, Chung Y, Zhang Y, Martinez GJ, Reynolds JM, Wang SL, Lin X, Sun SC, Lozano G and Dong C. The E3 ubiquitin ligase GRAIL regulates T cell tolerance and regulatory T cell function by mediating T cell receptor-CD3 degradation. Immunity 2010; 32: 670-680.
56. Schartner JM, Simonson WT, Wernimont SA, Nettenstrom LM, Huttenlocher A and Seroogy CM. Gene related to anergy in lymphocytes (GRAIL) expression in CD4+ T cells impairs actin cytoskeletal organization during T cell/antigen-presenting cell interactions. J Biol Chem 2009; 284: 34674-34681.
57. Sun SC. Non-canonical NF-kappaB signaling pathway. Cell Res 2011; 21: 71-85.
58. Giardino Torchia ML, Conze DB, Jankovic D and Ashwell JD. Balance between NF-kappaB p100 and p52 regulates T cell costimulation dependence. J Immunol 2013; 190: 549-555.
59. Giardino Torchia ML, Conze DB and Ashwell JD. c-IAP1 and c-IAP2 redundancy differs between T and B cells. PLoS One 2013; 8: e66161.
60. Perry WL, Hustad CM, Swing DA, O'Sullivan TN, Jenkins NA and Copeland NG. The itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a18H mice. Nat Genet 1998; 18: 143-146.
61. Fang D, Elly C, Gao B, Fang N, Altman Y, Joazeiro C, Hunter T, Copeland N, Jenkins N and Liu YC. Dysregulation of T lymphocyte function in itchy mice: a role for Itch in TH2 differentiation. Nat Immunol 2002; 3: 281-287.
62. Jin HS, Park Y, Elly C and Liu YC. Itch expression by Treg cells controls Th2 inflammatory responses. J Clin Invest 2013; 123: 4923-4934.
63. Lohr NJ, Molleston JP, Strauss KA, Torres-Martinez W, Sherman EA, Squires RH, Rider NL, Chikwava KR, Cummings OW, Morton DH and Puffenberger EG. Human ITCH E3 ubiquitin ligase deficiency causes syndromic multisystem autoimmune disease. Am J Hum Genet 2010; 86: 447-453.
64. Yang B, Gay DL, MacLeod MK, Cao X, Hala T, Sweezer EM, Kappler J, Marrack P and Oliver PM. Nedd4 augments the adaptive immune response by promoting ubiquitin-mediated degradation of Cbl-b in activated T cells. Nat Immunol 2008; 9: 1356-1363.
65. Ordureau A, Smith H, Windheim M, Peggie M, Carrick E, Morrice N and Cohen P. The IRAK-catalysed activation of the E3 ligase function of Pellino isoforms induces the Lys63-linked polyubiquitination of IRAK1. Biochem J 2008; 409: 43-52.
66. Chang M, Jin W, Chang JH, Xiao Y, Brittain GC, Yu J, Zhou X, Wang YH, Cheng X, Li P, Rabinovich BA, Hwu P and Sun SC. The ubiquitin ligase Peli1 negatively regulates T cell activation and prevents autoimmunity. Nat Immunol 2011; 12: 1002-1009.
67. Metzger MB, Hristova VA and Weissman AM. HECT and RING finger families of E3 ubiquitin ligases at a glance. J Cell Sci 2012; 125: 531-537.
68. Wang S, Li Y, Hu YH, Song R, Gao Y, Liu HY, Shu HB and Liu Y. STUB1 is essential for T-cell activation by ubiquitinating CARMA1. Eur J Immunol 2013; 43: 1034-1041.
69. Chen Z, Barbi J, Bu S, Yang HY, Li Z, Gao Y, Jinasena D, Fu J, Lin F, Chen C, Zhang J, Yu N, Li X, Shan Z, Nie J, Gao Z, Tian H, Li Y, Yao Z, Zheng Y, Park BV, Pan Z, Zhang J, Dang E, Li Z, Wang H, Luo W, Li L, Semenza GL, Zheng SG, Loser K, Tsun A, Greene MI, Pardoll DM, Pan F and Li B. The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3. Immunity 2013; 39: 272-285.
70. Sun L, Deng L, Ea CK, Xia ZP and Chen ZJ. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell 2004; 14: 289-301.
71. Xie JJ, Liang JQ, Diao LH, Altman A and Li Y. TNFR-associated factor 6 regulates TCR signaling via interaction with and modification of LAT adapter. J Immunol 2013; 190: 4027-4036.
72. King CG, Kobayashi T, Cejas PJ, Kim T, Yoon K, Kim GK, Chiffoleau E, Hickman SP, Walsh PT, Turka LA and Choi Y. TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat Med 2006; 12: 1088-1092.
73. Cejas PJ, Walsh MC, Pearce EL, Han D, Harms GM, Artis D, Turka LA and Choi Y. TRAF6 inhibits Th17 differentiation and TGF-beta-mediated suppression of IL-2. Blood 2010; 115: 4750-4757.
74. Muto G, Kotani H, Kondo T, Morita R, Tsuruta S, Kobayashi T, Luche H, Fehling HJ, Walsh M, Choi Y and Yoshimura A. TRAF6 is essential for maintenance of regulatory T cells that suppress Th2 type autoimmunity. PLoS One 2013; 8: e74639.
75. Espinosa A, Dardalhon V, Brauner S, Ambrosi A, Higgs R, Quintana FJ, Sjostrand M, Eloranta ML, Ni Gabhann J, Winqvist O, Sundelin B, Jefferies CA, Rozell B, Kuchroo VK and Wahren-Herlenius M. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med 2009; 206: 1661-1671.
76. Cai X, Srivastava S, Sun Y, Li Z, Wu H, Zuvela-Jelaska L, Li J, Salamon RS, Backer JM and Skolnik EY. Tripartite motif containing protein 27 negatively regulates CD4 T cells by ubiquitinating and inhibiting the class II PI3K-C2beta. Proc Natl Acad Sci U S A 2011; 108: 20072-20077.
77. Praefcke GJ, Hofmann K and Dohmen RJ. SUMO playing tag with ubiquitin. Trends Biochem Sci 2012; 37: 23-31.
78. Van Nguyen T, Angkasekwinai P, Dou H, Lin FM, Lu LS, Cheng J, Chin YE, Dong C and Yeh ET. SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation. Mol Cell 2012; 45: 210-221.
79. Lin BS, Tsai PY, Hsieh WY, Tsao HW, Liu MW, Grenningloh R, Wang LF, Ho IC and Miaw SC. SUMOylation attenuates c-Maf-dependent IL-4 expression. Eur J Immunol 2010; 40: 1174-1184.
80. Garaude J, Farras R, Bossis G, Charni S, Piechaczyk M, Hipskind RA and Villalba M. SUMOylation regulates the transcriptional activity of JunB in T lymphocytes. J Immunol 2008; 180: 5983-5990.
81. Terui Y, Saad N, Jia S, McKeon F and Yuan J. Dual role of sumoylation in the nuclear localization and transcriptional activation of NFAT1. J Biol Chem 2004; 279: 28257-28265.
82. Li Y, He X, Wang S, Shu HB and Liu Y. USP2a positively regulates TCR-induced NF-kappaB activation by bridging MALT1-TRAF6. Protein Cell 2013; 4: 62-70.
83. Kim EM, Lee HH, Kim SH, Son YO, Lee SJ, Han J, Bae J, Kim SJ, Park CG, Park Y, Hwang KW and Chun T. The mouse small ubiquitin-like modifier-2 (SUMO-2) inhibits interleukin-12 (IL-12) production in mature dendritic cells by blocking the translocation of the p65 subunit of NFkappaB into the nucleus. Mol Immunol 2011; 48: 2189-2197.
84. Kamitani T, Kito K, Nguyen HP and Yeh ET. Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein. J Biol Chem 1997; 272: 28557-28562.
85. Rabut G and Peter M. Function and regulation of protein neddylation. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep 2008; 9: 969-976.
86. Kumar S, Yoshida Y and Noda M. Cloning of a cDNA which encodes a novel ubiquitin-like protein. Biochem Biophys Res Commun 1993; 195: 393-399.
87. Pan ZQ, Kentsis A, Dias DC, Yamoah K and Wu K. Nedd8 on cullin: building an expressway to protein destruction. Oncogene 2004; 23: 1985-1997.
88. Xirodimas DP. Novel substrates and functions for the ubiquitin-like molecule NEDD8. Biochem Soc Trans 2008; 36: 802-806.
89. Li T, Santockyte R, Shen RF, Tekle E, Wang G, Yang DC and Chock PB. A general approach for investigating enzymatic pathways and substrates for ubiquitin-like modifiers. Arch Biochem Biophys 2006; 453: 70-74.
90. Jones J, Wu K, Yang Y, Guerrero C, Nillegoda N, Pan ZQ and Huang L. A targeted proteomic analysis of the ubiquitin-like modifier nedd8 and associated proteins. J Proteome Res 2008; 7: 1274-1287.
91. Del Rincon SV, Rogers J, Widschwendter M, Sun D, Sieburg HB and Spruck C. Development and validation of a method for profiling post-translational modification activities using protein microarrays. PLoS One 2010; 5: e11332.
92. Walden H, Podgorski MS and Schulman BA. Insights into the ubiquitin transfer cascade from the structure of the activating enzyme for NEDD8. Nature 2003; 422: 330-334.
93. Huang DT, Hunt HW, Zhuang M, Ohi MD, Holton JM and Schulman BA. Basis for a ubiquitin-like protein thioester switch toggling E1-E2 affinity. Nature 2007; 445: 394-398.
94. Huang DT, Paydar A, Zhuang M, Waddell MB, Holton JM and Schulman BA. Structural basis for recruitment of Ubc12 by an E2 binding domain in NEDD8's E1. Mol Cell 2005; 17: 341-350.
95. Kamura T, Conrad MN, Yan Q, Conaway RC and Conaway JW. The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. Genes Dev 1999; 13: 2928-2933.
96. Kurz T, Chou YC, Willems AR, Meyer-Schaller N, Hecht ML, Tyers M, Peter M and Sicheri F. Dcn1 functions as a scaffold-type E3 ligase for cullin neddylation. Mol Cell 2008; 29: 23-35.
97. Shen LN, Liu H, Dong C, Xirodimas D, Naismith JH and Hay RT. Structural basis of NEDD8 ubiquitin discrimination by the deNEDDylating enzyme NEDP1. EMBO J 2005; 24: 1341-1351.
98. Cope GA and Deshaies RJ. COP9 signalosome: a multifunctional regulator of SCF and other cullin-based ubiquitin ligases. Cell 2003; 114: 663-671.
99. Brownell JE, Sintchak MD, Gavin JM, Liao H, Bruzzese FJ, Bump NJ, Soucy TA, Milhollen MA, Yang X, Burkhardt AL, Ma J, Loke HK, Lingaraj T, Wu D, Hamman KB, Spelman JJ, Cullis CA, Langston SP, Vyskocil S, Sells TB, Mallender WD, Visiers I, Li P, Claiborne CF, Rolfe M, Bolen JB and Dick LR. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell 2010; 37: 102-111.
100. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S, Cullis CA, Doucette A, Garnsey JJ, Gaulin JL, Gershman RE, Lublinsky AR, McDonald A, Mizutani H, Narayanan U, Olhava EJ, Peluso S, Rezaei M, Sintchak MD, Talreja T, Thomas MP, Traore T, Vyskocil S, Weatherhead GS, Yu J, Zhang J, Dick LR, Claiborne CF, Rolfe M, Bolen JB and Langston SP. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009; 458: 732-736.
101. Lin JJ, Milhollen MA, Smith PG, Narayanan U and Dutta A. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res 2010; 70: 10310-10320.
102. Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, Dick LR, Garnsey JJ, Koenig E, Langston SP, Manfredi M, Narayanan U, Rolfe M, Staudt LM, Soucy TA, Yu J, Zhang J, Bolen JB and Smith PG. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 2010; 116: 1515-1523.
103. Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K, Padmanabhan S, O'Dwyer M, Nawrocki ST, Giles FJ and Carew JS. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 2010; 115: 3796-3800.
104. Wang M, Medeiros BC, Erba HP, DeAngelo DJ, Giles FJ and Swords RT. Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer. Expert Opin Ther Targets 2011; 15: 253-264.
105. Chen Y, Neve RL and Liu H. Neddylation dysfunction in Alzheimer's disease. J Cell Mol Med 2012; 16: 2583-2591.
106. Watson IR, Irwin MS and Ohh M. NEDD8 pathways in cancer, Sine Quibus Non. Cancer Cell 2011; 19: 168-176.
107. Panattoni M, Sanvito F, Basso V, Doglioni C, Casorati G, Montini E, Bender JR, Mondino A and Pardi R. Targeted inactivation of the COP9 signalosome impairs multiple stages of T cell development. J Exp Med 2008; 205: 465-477.
108. Menon S, Chi H, Zhang H, Deng XW, Flavell RA and Wei N. COP9 signalosome subunit 8 is essential for peripheral T cell homeostasis and antigen receptor-induced entry into the cell cycle from quiescence. Nat Immunol 2007; 8: 1236-1245.
109. Wei N and Deng XW. The COP9 signalosome. Annu Rev Cell Dev Biol 2003; 19: 261-286.
110. Jin HS, Liao L, Park Y and Liu YC. Neddylation pathway regulates T-cell function by targeting an adaptor protein Shc and a protein kinase Erk signaling. Proc Natl Acad Sci U S A 2013; 110: 624-629.
111. Friend SF, Peterson LK, Treacy E, Stefanski AL, Sosinowski T, Pennock ND, Berger AJ, Winn VD and Dragone LL. The Discovery of a Reciprocal Relationship between Tyrosine-Kinase Signaling and Cullin Neddylation. PLoS One 2013; 8: e75200.
112. Sakaguchi N, Takahashi T, Hata H, Nomura T, Tagami T, Yamazaki S, Sakihama T, Matsutani T, Negishi I, Nakatsuru S and Sakaguchi S. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 2003; 426: 454-460.
113. Locke NR, Patterson SJ, Hamilton MJ, Sly LM, Krystal G and Levings MK. SHIP regulates the reciprocal development of T regulatory and Th17 cells. J Immunol 2009; 183: 975-983.
114. Bogunovic D, Boisson-Dupuis S and Casanova JL. ISG15: leading a double life as a secreted molecule. Exp Mol Med 2013; 45: e18.
115. Lukasiak S, Schiller C, Oehlschlaeger P, Schmidtke G, Krause P, Legler DF, Autschbach F, Schirmacher P, Breuhahn K and Groettrup M. Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. Oncogene 2008; 27: 6068-6074.